Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099607 | 0.88 | MET (0.39) | GPR119IDO1TDO2 | |
| SCHEMBL21050917 | 0.88 | SMARCA2 (0.38) | SMARCA2SMARCA4PBRM1GPR119IDO1 | |
| SCHEMBL21050985 | 0.86 | MDM2 (0.33) | — | |
| SCHEMBL21136722 | 0.82 | MAP4K4 (0.42) | SMARCA2SMARCA4PBRM1GPR119POLB | |
| SCHEMBL21099361 | 0.82 | MET (0.39) | GPR119IDO1TDO2 | |
| SCHEMBL21137316 | 0.82 | MET (0.39) | GPR119IDO1TDO2 | |
| SCHEMBL21099203 | 0.82 | MET (0.39) | GPR119IDO1TDO2 | |
| SCHEMBL21136721 | 0.81 | — | — | |
| SCHEMBL21099612 | 0.79 | KRAS (0.50) | SMARCA2SMARCA4PBRM1GPR119IDO1 | |
| SCHEMBL21099365 | 0.78 | KRAS (0.49) | GPR119IDO1TDO2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | SMARCA2 2068/4885SMARCA4 1478/4885PBRM1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.